Hansoh Pharma stock fell 3.29 percent on October 2 as obesity data arrived
Published on 10/04/2026 at 15:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hansoh Pharma stock fell 3.29 percent to HKD 34.140 on October 2, 2026, as investors weighed fresh Phase III obesity data against a valuation-sensitive pipeline. Boerse.de reported on October 2 that Hansoh's olatorepatide reached mean weight loss of 19.3 percent at Week 48 in the 15 mg group.
Obesity data strengthen the pipeline
The LIGHTEN study enrolled 604 Chinese adults with overweight or obesity and compared three weekly olatorepatide doses with placebo. The 15 mg group recorded 19.3 percent weight loss, versus 2.7 percent in the placebo group, a 22.0 percentage point gap.
The result also showed a 16.0 centimeter mean reduction in waist circumference at 15 mg. Gastrointestinal event rates included nausea at 7.8 percent and vomiting at 4.9 percent, giving the data a potential differentiation point as Hansoh advances its metabolic portfolio.
Profit growth broadens the story
Hansoh's financial base adds scale to the clinical narrative. In the first half of 2026, revenue reached CNY 8.304 billion, up 11.7 percent year over year, while profit rose 35.8 percent to CNY 4.258 billion, according to VCBeat in a September 23, 2026 report.
Innovative medicines generated CNY 7.092 billion in the same half-year period and represented 85.4 percent of revenue. The figures show that earnings growth is already being supported by the innovative-drug portfolio, while the obesity candidate remains a development-stage asset.
Stock remains below its yearly high
Hansoh Pharma was last at HKD 34.140 on the Hong Kong Stock Exchange on October 2, 2026 at 4:08 p.m. HKT, with a daily change of minus 3.29 percent. The price stood between the session low of HKD 33.640 and high of HKD 34.660.
The stock's 52-week range was HKD 28.060 to HKD 44.220, putting the October 2 price HKD 10.080 below the yearly high. Market capitalization was HKD 207.0 billion and trading volume reached 15,590,681 shares.
Pipeline progress meets execution risk
Hansoh's oncology and immunology programs remain central to the next stage of growth. The company's official September 14, 2026 release said its HS-10370 combination produced an 81.5 percent confirmed response rate in a Phase Ib study, while the 12-month progression-free survival rate was 78.7 percent.
For investors, the key issue is conversion from trial success into approvals and commercial sales. The obesity results improve the pipeline profile, but the October 2 decline shows that strong clinical figures can still compete with valuation and delivery concerns.
Hansoh Pharma stock facts
- Company: Hansoh Pharmaceutical Group Company Limited
- Ticker: 3692
- Trading venue: Hong Kong Stock Exchange
- Closing price (October 2, 2026): HKD 34.140
- Market capitalization: HKD 207.0 billion (as of October 2, 2026)
- 52-week range: HKD 28.060-44.220 (as of October 2, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
